Preoperative Management of Apixaban for Knee Surgery in High-Risk VTE Patient
Stop apixaban 48 hours (2 days) before knee surgery, with no bridging anticoagulation required despite the patient's history of multiple DVTs. 1
Timing of Apixaban Discontinuation
Knee surgery is classified as a high hemorrhagic risk procedure requiring adequate drug clearance before the operation. The FDA label for Eliquis explicitly states that apixaban should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding 1. The 2022 American College of Chest Physicians guidelines similarly recommend 2 days off before high-bleed-risk procedures for apixaban 2.
This 48-hour window applies regardless of whether the patient is taking apixaban for atrial fibrillation or VTE treatment 2. The French perioperative hemostasis guidelines (GIHP) recommend stopping apixaban 3 days before the procedure when creatinine clearance is >30 mL/min 3, though this is slightly more conservative than the FDA recommendation.
Key consideration: Verify the patient's creatinine clearance (using Cockcroft-Gault formula) before finalizing the timing, as renal impairment would require longer interruption periods 3.
No Bridging Anticoagulation Needed
Despite this patient's history of multiple DVTs, bridging with heparin is NOT recommended. The FDA label explicitly states that "bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required" 1.
The French guidelines reinforce this, stating "there is no need for preoperative heparin bridging (UFH or LMWH) except for very thrombotic high-risk" 3. While a history of multiple DVTs raises concern, the rapid offset and onset of apixaban's anticoagulant effect makes bridging unnecessary in most cases 2.
Exception to consider: If the patient is in the early phase of an acute DVT (actively being treated with high-dose apixaban 10 mg twice daily), a multidisciplinary discussion is warranted as standard protocols may not apply 3.
Verification of Adequate Drug Clearance
Research demonstrates that apixaban discontinuation for at least 48 hours results in clinically insignificant anticoagulation prior to surgery. A prospective study showed 94% of patients achieved apixaban concentrations ≤30 ng/mL with a median cessation time of 76 hours 4.
Avoid neuraxial anesthesia (spinal or epidural) if there is any possibility of residual apixaban concentration, particularly in elderly patients or those with renal impairment 3.
Postoperative Resumption Strategy
After knee surgery, follow this sequence:
Immediate postoperative period (6-24 hours): Start prophylactic-dose heparin (UFH or LMWH) or fondaparinux at least 6 hours after surgery once hemostasis is adequate 3
Therapeutic anticoagulation (24-72 hours): Resume apixaban at therapeutic dose 24-72 hours postoperatively when surgical hemostasis is confirmed 3
Timing with prophylactic LMWH: If using LMWH bridging, give the first therapeutic dose of apixaban 12 hours after the last prophylactic LMWH dose 3
With epidural catheter: If an epidural catheter is present, use heparin for therapeutic anticoagulation until the catheter can be safely removed, then transition to apixaban 3
Critical Pitfalls to Avoid
- Do not check INR to guide apixaban cessation or resumption—apixaban affects INR measurements and they are not useful for monitoring 1
- Do not routinely bridge with heparin based solely on VTE history—this increases bleeding risk without proven benefit
- Do not perform neuraxial anesthesia within 48 hours of the last apixaban dose
- Monitor postoperative renal function as surgery may affect kidney function and require dose adjustment of resumed apixaban 3
- Check for P-glycoprotein or CYP3A4 inhibitors that may prolong apixaban clearance and require extended cessation 3